2005 news releases and statements

13/12/2005
Innovation in diabetes care: New ways for people to take insulin; New compounds under development
07/12/2005
New ABPI President Named
07/12/2005
ABPI Pharmacy Awards Enter Second Year
16/11/2005
New report on cancer reveals majority of patients don't understand their condition
16/11/2005
New Code of practice for pharmaceutical industry revealed
09/11/2005
"Partnership for action" vital for future science skills, says new ABPI study
03/11/2005
Faster Medicines Guidance from NICE: ABPI Statement
25/10/2005
ABPI Supports MHRA Patient Reporting Scheme
13/10/2005
Medicines Trade Balance Dips
21/09/2005
Pharmaceutical Industry Launches Web Portal To Aid Access To Clinical Trial Data
13/09/2005
OFT study: ABPI statement
12/09/2005
Facing the challenge of heart disease and diabetes for Scotland's future
01/09/2005
Government Response To Health Select Committee Report: ABPI Statement
23/08/2005
Closure of Darley Oaks Guinea Pig Farm - Statement from the ABPI
02/08/2005
Scottish press release: Positive audit recommendations must not be used as excuse for cheap prescribing
01/08/2005
Fewer but more agressive animal extremist attacks recorded
29/07/2005
Counterfeit medicines: ABPI statement
22/07/2005
How the pharmaceutical industry and the NHS can work together
19/07/2005
NICE's proposed decision on Alzheimer's "a blow for patients"
19/07/2005
Now booking for IoD/ABPI Diploma in Company Direction 05/06
01/07/2005
Website link to clinical trials databases set up
01/07/2005
New government legislaton on animal rights extremists must be enforced, says ABPI
28/06/2005
First ABPI Pharmacists Awards made
14/06/2005
Helping those who oversee medicines trials
09/06/2005
More medicines being developed for breast cancer than ever, report shows
08/06/2005
Doctors' and Pharmaceutical companies' framework welcomed
25/05/2005
ABPI welcomes Nuffield animals in science report
09/05/2005
Lecturer post for ABPI Commercial Affairs Director
05/05/2005
Code review attracts strong response
27/04/2005
Guide to PPRS published by ABPI
07/04/2005
Proposals to reverse science graduate decline welcomed by ABPI
07/04/2005
Passage of Crime Bill will protect UK science, say ABPI
05/04/2005
Response to Health Select Committee report 'The Influence of the Pharmaceutical Industry'
05/04/2005
Warning from ABPI as key Pharmaceutical Industry Indicators slip
01/03/2005
NICE's draft recommendations on Alzheimer's Medicines are blow to patients and to future research, says ABPI
18/02/2005
ABPI launches Paediatric trials guide
08/02/2005
Education system failing to provide top scientists needed by research - based pharmaceutical industry
01/02/2005
Pharmaceutical industry backs '3R's' centre with sponsorship of new post
31/01/2005
Pharmaceutical Industry Applauds Determination To End Animal Extremism
27/01/2005
Pharmaceutical Industry Backs ‘3Rs’ Centre With Sponsorship Of New Post
19/01/2005
Animal extremists' intimidation scares off companies suppliers
13/01/2005
ABPI makes key recommendations to House of Commons Select Committee inquiry
06/01/2005
Asian tsunami disaster: relief aid by pharmaceutical companies
06/01/2005
Global clinical trial register gets UK pharmaceutical industry backing

Print this page

Get in touch

Please choose the subject of your enquiry from the list below:

Enter the above code here:

Can't read? Try different words.

Submit

I am happy for ABPI to keep my details on file and to send me details of future ABPI work and services. ABPI will not sell your data to any third party or send you any information about products or services that ABPI has no direct connection with.

The Association of the British Pharmaceutical Industry

7th floor, Southside, 105 Victoria Street,
London, SW1E 6QT
Telephone +44 (0) 870 890 4333
ABPI Cymru Wales
ABPI Northern Ireland
ABPI Scotland

The Prescription Medicines Code of Practice Authority (PMCPA) is responsible for administering the ABPI Code of Practice for the Pharmaceutical Industry at arm's length of the ABPI itself.

The Office of Health Economics (OHE) provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.